Clinical Trial Update: Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of ACT-541468 (Daridorexant) in adults with insomnia disorder has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia Disorder

Drugs mentioned

• ACT-541468 (Daridorexant) (daridorexant)

Snippet

Sponsor: Idorsia Pharmaceuticals Ltd. | Conditions: Insomnia Disorder | Phase 3 | Status: COMPLETED | Results posted: 2022-03-25